microApplication Note – microHeart® Cell Ready

Screening Compounds with Known Cardiotoxicities Using the StemoniX® microHeart® Platform

The removal of approved drugs from the market, as well as late-stage failures in clinical trials, is often linked to unforeseen cardiac toxicity. To address this problem, independent organizations, including the Food and Drug Administration (FDA), pharmaceutical companies, contract research organizations, and academic institutions, are evaluating human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a complementary tool for the toxicity and safety assessment of therapeutic compounds. hiPSC-CMs are also an integral component of a new paradigm, the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, through which panels of compounds with known mechanism of cardiotoxicity are being evaluated in hiPSC-CM platforms across independent test sites using a number of novel cutting-edge technologies.

  • microHeart provides a biologically relevant,
    consistent, and reproducible platform for high throughput drug screening and cardiac safety studies
  • Greater resolution of proarrhythmic phenotypes was observed in 60% of the CiPA compounds in microHeart compared to conventional screening plates
  • All compounds in the CiPA high risk category showed a dose dependent progression in the severity of proarrhythmic events

Ordering Information

Product Name Catalog #
microHeart Cell Ready 96-well Plate MHCRX-AA-0096
microHeart Cell Ready 384-well Plate MHCRX-AA-0384
microHeart Cell Ready 1536-well Plate Call for Information
microHeart Assay Ready 96-Well Plate MHARX-AA-0096
microHeart Assay Ready 384-Well Plate MHARX-AA-0384

Want to read the entire microApplication Note – microHeart® CiPA?

Fill out the form and we’ll email you the PDF.